NLRP12 Suppresses Colon Inflammation and Tumorigenesis through the Negative Regulation of Noncanonical NF-κB Signaling
2012; Cell Press; Volume: 36; Issue: 5 Linguagem: Inglês
10.1016/j.immuni.2012.03.012
ISSN1097-4180
AutoresIrving C. Allen, Justin E. Wilson, Monika Schneider, John D. Lich, Reid A. Roberts, Janelle C. Arthur, Rita-Marie T. Woodford, Beckley K. Davis, Joshua M. Uronis, Hans Herfarth, Christian Jobin, Arlin B. Rogers, Jenny P.‐Y. Ting,
Tópico(s)Immune Response and Inflammation
ResumoIn vitro data suggest that a subgroup of NLR proteins, including NLRP12, inhibits the transcription factor NF-κB, although physiologic and disease-relevant evidence is largely missing. Dysregulated NF-κB activity is associated with colonic inflammation and cancer, and we found Nlrp12(-/-) mice were highly susceptible to colitis and colitis-associated colon cancer. Polyps isolated from Nlrp12(-/-) mice showed elevated noncanonical NF-κB activation and increased expression of target genes that were associated with cancer, including Cxcl13 and Cxcl12. NLRP12 negatively regulated ERK and AKT signaling pathways in affected tumor tissues. Both hematopoietic- and nonhematopoietic-derived NLRP12 contributed to inflammation, but the latter dominantly contributed to tumorigenesis. The noncanonical NF-κB pathway was regulated upon degradation of TRAF3 and activation of NIK. NLRP12 interacted with both NIK and TRAF3, and Nlrp12(-/-) cells have constitutively elevated NIK, p100 processing to p52 and reduced TRAF3. Thus, NLRP12 is a checkpoint of noncanonical NF-κB, inflammation, and tumorigenesis.
Referência(s)